Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Receivables - Net: 2024-2025

Historic Receivables - Net for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Sep 2025 value amounting to $16.7 million.

  • Day One Biopharmaceuticals' Receivables - Net rose 92.03% to $16.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.7 million, marking a year-over-year increase of 92.03%. This contributed to the annual value of $13.9 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Receivables - Net stood at $16.7 million, which was down 15.11% from $19.7 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Receivables - Net high stood at $19.7 million for Q2 2025, and its period low was $8.7 million during Q3 2024.
  • For the 2-year period, Day One Biopharmaceuticals' Receivables - Net averaged around $14.4 million, with its median value being $15.3 million (2024).
  • Data for Day One Biopharmaceuticals' Receivables - Net shows a peak YoY surged of 115.29% (in 2025) over the last 5 years.
  • Day One Biopharmaceuticals' Receivables - Net (Quarterly) stood at $13.9 million in 2024, then skyrocketed by 92.03% to $16.7 million in 2025.
  • Its last three reported values are $16.7 million in Q3 2025, $19.7 million for Q2 2025, and $18.1 million during Q1 2025.